Collectionner le produit
Détails du produit
Synonyms
TFPI, LACI, TFPI1, EPI, TFI
Source
Human TFPI, His Tag (TFI-H5226) is expressed from human 293 cells (HEK293). It contains AA Asp 29 - Lys 282 (Accession # NP_006278.1).
Predicted N-terminus: Asp 29
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 30.0 kDa. The protein migrates as 41-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human TFPI, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity
Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate,Mca-RPKPVE-Nval-WRK(Dnp)-NH2 Fluorogenic MMP Substrate. The IC50 value is <0.50 nM, as measured under the described conditions (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Tissue factor pathway inhibitor
- Catégorie：
- Nombre de médicaments répertoriés：
2 Détails
- Nombre de médicaments cliniques：
3 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
